HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
YCBD
cbdMD, Inc.
YCBD lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
YCBD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Strong |
YCBD's revenue and balance sheet are currently healthy, but its profitability and cash flow are weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
YCBD PE Valuation
YCBD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
YCBD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
YCBD has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
YCBD has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus YCBD down 100%.
YCBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$71.92 | +$66.48 |
| Q1 2024 | -$80.00 | +$247.12 |
| Q4 2023 | -$83.12 | +$266.08 |
| Q3 2023 | -$106.56 | +$339.84 |
| Q2 2023 | -$138.40 | +$246.80 |
| Q1 2023 | -$327.12 | -$147.12 |
| Q4 2022 | -$349.20 | -$118.80 |
| Q3 2022 | -$446.40 | -$277.20 |
YCBD lost $0.40 per share over the past year, a smaller loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over YCBD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over YCBD on profitability, with a higher operating margin.
YCBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.6M | +21% |
| Q1 2026 | $5.6M | +19% |
| Q4 2025 | $5M | -1.9% |
| Q3 2025 | $4.7M | +3.6% |
| Q2 2025 | $4.6M | -11% |
| Q1 2025 | $4.7M | +8.5% |
| Q4 2024 | $5.1M | -4.9% |
| Q3 2024 | $4.6M | -20% |
YCBD's revenue is recovering but still below its 2020 peak: $6M last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -20% | -0.7 points |
| Q1 2026 | -14% | -4 points |
| Q4 2025 | -5.7% | -4 points |
| Q3 2025 | -15% | -7.6 points |
| Q2 2025 | -20% | -12 points |
| Q1 2025 | -10% | +25 points |
| Q4 2024 | -1.7% | +18 points |
| Q3 2024 | -7% | +260 points |
YCBD's operating margin was −20% last quarter, down 0.7 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over YCBD on cash generation, producing positive trailing cash flow while its opponent burns cash.
YCBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$460.2K | +$245.5K |
| Q3 2025 | -$243.6K | -255% |
| Q2 2025 | -$705.7K | -344% |
| Q3 2024 | $157.4K | +$541.1K |
| Q2 2024 | $289.8K | +$632.7K |
| Q1 2024 | -$699.4K | +$931.8K |
| Q4 2023 | -$290.5K | +$2M |
| Q3 2023 | -$383.7K | +$1.8M |
YCBD has burned cash in most quarters: −$2M over the past year, against −$957,967 the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over YCBD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
YCBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +173K shares |
| 1 year | +1264% | +9.8M shares |
| 3 years | +6297% | +10.5M shares |
| 5 years | +10137% | +10.5M shares |
YCBD has 11M diluted shares, up 1264% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
YCBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | -0.4x | Net Cash |
| Q1 2020 | -1.6x | Net Cash |
YCBD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
YCBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.1 | Neutral |
YCBD's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
YCBD PE vs Healthcare Sector
YCBD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
YCBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.40 | 2.5% below |
| 20 week MA | $0.49 | 20% below |
| 50 week MA | $0.73 | 47% below |
| 100 week MA | $1.23 | 68% below |
| 200 week MA | $9.57 | 96% below |
YCBD is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over YCBD on returns for 2026, with the stronger performance.
YCBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $932.4 | $1,123.2 | +20% |
| 2021 | $1,123.2 | $406.8 | -64% |
| 2022 | $406.8 | $90.0 | -78% |
| 2023 | $90.0 | $8.32 | -91% |
| 2024 | $8.32 | $3.02 | -64% |
| 2025 | $3.02 | $1.68 | -44% |
| 2026 YTD | $1.68 | $0.39 | -77% |
YCBD has finished five years in a row lower, and it's down 77% so far in 2026.